Mandate, objectives and rules of procedure for the Cancer Medicines Forum

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 12, Status: Authorised

Bimervax: Periodic safety update report assessment 30 September 2024 - 29 March 2025

Concept paper on the guideline revision on good pharmacogenomic practice

Human medicines European public assessment report (EPAR): Loargys, pegzilarginase, Date of authorisation: 15/12/2023, Revision: 5, Status: Authorised

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting with all eligible organisations - 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 November 2025, 09:00 (CET) to 18 November 2025, 17:30 (CET)

Meeting summary - PCWP/HCPWP and all eligible organisations meeting 18 November 2025

Human medicines European public assessment report (EPAR): Inbrija, levodopa, Date of authorisation: 19/09/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Gohibic, vilobelimab, Date of authorisation: 13/01/2025, Revision: 2, Status: Authorised